États-Unis · Plateformes & données · Morningstar

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

Publié par Morningstar · États-Unis il y a 9 h

The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

À lire aussi

Vor Biopharma Inc. (VOR) - What Are Investment Firms Thinking About This Stock?

Zai Lab announces $250M private placement

We have a $300,000 mortgage with a 2.75% interest rate. I want to pay it off. My husband says I’m crazy. Who’s right?

This Top Investment Strategist Thinks a Bitcoin Supercycle Is Coming Soon. Here's Why He's Wrong.

OpenAI and Poland’s NASK collaborate on AI safety research

Gold Falls Below $4,000 for the First Time Since July. What’s Next?

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

Partager

À lire aussi

Vor Biopharma Inc. (VOR) - What Are Investment Firms Thinking About This Stock?

Zai Lab announces $250M private placement

We have a $300,000 mortgage with a 2.75% interest rate. I want to pay it off. My husband says I’m crazy. Who’s right?

This Top Investment Strategist Thinks a Bitcoin Supercycle Is Coming Soon. Here's Why He's Wrong.

OpenAI and Poland’s NASK collaborate on AI safety research

Gold Falls Below $4,000 for the First Time Since July. What’s Next?